logo-loader
/**/ h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:10.0pt;font-family:"Times New Roman","serif";text-transform:uppercase;}h2{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:10.0pt;font-family:"Times New Roman","serif";}h3{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h5{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .em{size:21.0cm 841.95pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.em{}p.fr{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.fp{font-size:12.0pt}p.aa,li.aa,div.aa{margin:0cm;margin-bottom:.0001pt;line-height:13.0pt;font-size:11.0pt;font-family:"Times New Roman","serif";}p.fs{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}p.ft{margin:0cm;margin-bottom:.0001pt;line-height:13.0pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";}p.fu{margin:0cm;margin-bottom:.0001pt;line-height:13.0pt;font-size:11.0pt;font-family:"Times New Roman","serif";line-height:normal}table.fv{margin-left:-5.4pt;border-collapse:collapse;border:none} td.fj{width:14.65pt;border:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.fw{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: normal; margin-top: 0cm; text-align: left}td.fi{width:185.6pt;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.fh{width:55.65pt;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.fg{width:31.6pt;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.ff{width:48.65pt;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.fe{width:26.95pt;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.fd{width:54.05pt;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.fb{width:14.65pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt}p.fx{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:13.0pt;font-size:11.0pt;font-family:"Times New Roman","serif";line-height: normal; margin-top: 0cm; text-align: left} td.fa{width:185.6pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ey{width:55.65pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.ez{font-size:10.0pt;font-family:"Arial","sans-serif"}td.ex{width:31.6pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.ew{width:48.65pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ev{width:26.95pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.eu{width:54.05pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.fy{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-autospace:none}p.fz{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.ef{} p.ga{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.eh{}table.gb{margin-left:-5.4pt;border-collapse:collapse}td.eq{width:334.8pt;padding:0cm 5.4pt 0cm 5.4pt}td.ep{width:136.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.gc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align:justify} /**/
RNS Number : 5813B
Circassia Pharmaceuticals Plc
07 June 2019
 

7 June 2019

 

Circassia Pharmaceuticals plc

 

Result of Annual General Meeting 2019 and Re Directorate

 

Circassia Pharmaceuticals plc ("Circassia") announces that at its Annual General Meeting held today all resolutions set out in the notice of Annual General Meeting dated 1 May 2019 were passed.  A poll was conducted on each resolution proposed at the Meeting and the number of votes cast for and against each of the resolutions, and the number of votes withheld, were as follows:

 


Resolution

For

%

Against

%

Withheld*

1

To receive the Annual report and accounts

322,919,875

100.00

13

0.00

7,000

2

To approve the Directors' Annual report on remuneration

322,890,903

99.99

33,885

0.01

2,100

3

To approve the Directors' Remuneration policy

321,934,551

99.69

990,237

0.31

2,100

4

To approve amendments to the rules of the Circassia Pharmaceuticals plc Performance Share Plan

321,937,169

99.99

29,184

0.01

960,535

5

To re-elect Francesco Granata

322,893,492

99.99

26,296

0.01

7,100

6

To re-elect Steven Harris

322,893,492

99.99

26,296

0.01

7,100

7

To re-elect Julien Cotta

321,944,717

99.99

23,636

0.01

958,535

8

To re-elect Rod Hafner

322,893,459

99.99

26,329

0.01

7,100

9

To re-elect Jo le Couilliard

322,896,152

99.99

23,636

0.01

7,100

10

To re-elect Sharon Curran

322,896,152

99.99

18,636

0.01

12,100

11

To re-appoint PricewaterhouseCoopers LLP as Auditors

321,962,457

99.70

956,141

0.30

8,290

12

To give authority to determine the Auditors' remuneration

322,896,152

99.99

16,636

0.01

14,100

13

To give authority to allot shares

322,890,902

99.99

23,886

0.01

12,100

14

To give authority to disapply pre-emption rights**

322,889,262

99.99

22,288

0.01

15,788

15

To give authority to disapply pre-emption rights in respect of an additional 5% of the Company's issued share capital**

321,939,017

99.70

973,723

0.30

14,598

 

* A vote withheld is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

** Special resolution.

 

As previously announced Russ Cummings did not seek re-election at the Annual General Meeting and accordingly has today stepped down as a Director.

 

For enquiries, contact:

 

Julien Cotta, Company Secretary

Tel: +44 (0)1865 405560

 

Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Dr Christopher Golden

Tel: +44 (0) 20 7418 8900

 

Numis Securities (Joint Broker)

James Black / Freddie Barnfield

Tel: +44 (0) 20 7260 1000

 

FTI Consulting

Simon Conway / Ciara Martin

Tel: +44 (0) 20 3727 1000

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGLLFLERDIDIIA

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.05

Market: LSE
Market Cap: £63.97 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19